Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists

Autores de IIS La Fe

• Hortensia Ferrero Chafer

  Autor

• Carmen Maria Garcia Pascual

  Autor

• Carlos Simon Valles

  Autor

• Francisco Gaytan Luna

  Autor

• Antonio Pellicer Martínez

  Autor

Participantes ajenos a IIS La Fe

• Gómez R
• Delgado-Rosas F
• Cauli O

Grupos

• Medicina Reproductiva

  

  Investigador Principal

  José Morales Roselló

Abstract

Objective: To ascertain whether vascular endothelial growth factor (VEGF) secretion by luteinized granulosa cells (GCs) is modulated by the dopaminergic system in a dose-dependent fashion and how this is related to the differential efficacy of dopamine receptor 2 (D2)-agonists (D2-ag) in preventing ovarian hyperstimulation syndrome (OHSS). Design: The relationship between the dopaminergic system and VEGF secretion in luteinized GCs was evaluated. Archived human ovaries were immunostained to characterize D2 expression. Setting: University affiliated infertility center. Patient(s): Premenopausal women and egg donors. Intervention(s): Luteinized GCs were cultured with the D2-ag cabergoline. Human ovarian sections were immunostained for D2. Main Outcome Measure(s): The VEGF was measured by ELISA and D2 expression was evaluated by In-Cell ELISA. The D2 expression throughout the luteal phase was characterized by immunohistochemistry. Result(s): The VEGF secretion was decreased by the D2-ag in a dose-dependent fashion. The efficiency of this process was correlated with the amount of D2 expressed by luteinized GCs. A decrease in D2 expression in ovarian sections was observed during the late luteal phase. Conclusion(s): The efficacy of D2-ags in preventing OHSS might rely on their capacity to inhibit VEGF secretion by luteinized GCs. Because this capacity is dose-dependent, increasing the intraovarian concentration of D2-ags should be explored as a means of increasing the efficacy of these drugs in preventing OHSS. (C) 2014 by American Society for Reproductive Medicine.

Keywords

• OHSS; VEGF; granulosa cells; dopamine receptor 2; dopamine receptor 2 agonist